Doximity stock has had a difficult five year run, with the share price down 71.8%. However, the current valuation checks suggest the picture today is more nuanced, as the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while the market based multiples look closer to fair.

• Over the past five years, Doximity has delivered a share price decline of 71.8%, which means anyone looking at the stock now is likely focused on whether that weakness has already been reflected in expectations.
• Recent enthusiasm around Doximity's AI powered tools can support higher growth assumptions, while any disappointment in how quickly those products translate into lasting revenue and cash flow may weigh on what investors are willing to pay.
• Doximity scores 4 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether the current share price still leaves enough margin of safety, given the DCF estimate suggests Doximity is about 30.8% below intrinsic value while the market multiples read as about right.

Is Doximity a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Doximity can generate for shareholders and discounts it back to today. For Doximity, the model uses latest twelve month free cash flow of about $298 million and assumes that cash flows continue to grow rather than contract, which suits a company investing heavily in AI tools.

On these assumptions, the DCF model points to an estimated intrinsic value of about $36 per share. That implies the stock is 30.8% below this cash flow based estimate and screens as undervalued on this measure. Because the recent AI powered products have already lifted revenue guidance, the strong news flow helps explain why some investors now view the gap between price and intrinsic value as less one sided.

On the DCF model, Doximity stock currently looks undervalued relative to the cash flows analysts expect it to produce.

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 30.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Where Does Doximity Sit on Earnings?

P/E is a useful cross check for Doximity because the company is profitable and investors follow earnings closely. On this metric, Doximity trades on a P/E of about 26.6x, which is slightly below the Healthcare Services industry average of roughly 29.8x and well below a peer group average of about 56.9x.

The fair P/E for Doximity, based on its growth profile, margins, size and risk, is estimated at about 25.6x. That is very close to where the stock changes hands today, so the current P/E does not point to a clear discount or premium relative to what the model would expect.

On the P/E multiple, Doximity stock appears roughly fairly valued compared with both its industry and a tailored fair value range.

The Doximity Narrative: What Would Justify Today's Price?

For Doximity, Simply Wall St Narratives pick up where the valuation puzzle leaves off and set out what kind of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. Instead of a single headline figure from a ratio or model, they describe the underlying path those numbers rely on so you can track how Doximity's actual progress compares over time on the Community page.

The community is split on Doximity, with some investors seeing an underappreciated physician network while others focus on rising costs and competition.

Bull case: 26% undervalued

"Lately I’ve also tried some of their clinical AI tools and have been surprisingly impressed by how good they are and the quality…"

Bear case: 39% overvalued

"Tightening regulation around digital data privacy is poised to increase compliance costs for Doximity, potentially limiting the effectiveness of its data-driven advertising products and workflow tools, which could compress future operating margins and restrict core ad revenue growth…"

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

The Bottom Line

Doximity appears undervalued on a Discounted Cash Flow (DCF) view, with the intrinsic value estimate sitting well above the current share price. The market multiple view is closer to fair value, which points to a mixed valuation picture rather than a clear bargain. The gap between the two mainly comes down to how confidently investors view future cash flows from Doximity's AI tools compared with the more cautious perspective implied by current P/E levels. The key question from here is whether those products can translate into durable revenue and cash flow that align with the intrinsic value estimate instead of the market's more restrained stance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.